Carmen La Rosa

2.6k citations

71 papers · 1.8k indexed · 2 hit papers · h-index 22

Immunology top 5%
Physiology top 5%
Pulmonary and Respiratory Medicine top 10%
Dermatology top 1%
Epidemiology top 10%

Co-authors: Qing Li Kim Papp Kristian Reich Aimee Campbell N. Cichanowitz Andrew Blauvelt Alexa B. Kimball Diamant Thaçi
Topics: Respiratory and Cough-Related Research (22 papers)Asthma and respiratory diseases (13 papers)Voice and Speech Disorders (12 papers)
Cited by: Dermatology Immunology Physiology
Journals: The Lancet American Journal of Respiratory and Critical Care Medicine Journal of Consulting and Clinical Psychology
Partner nations: United States United Kingdom Canada

In The Last Decade

Carmen La Rosa

67 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

2017 413 citations Kristian Reich, Kim Papp et al. profile →
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

2022 178 citations Lorcan McGarvey, Surinder S. Birring et al. profile →

Peers

Countries citing papers authored by Carmen La Rosa

Since Specialization

Citations

This map shows the geographic impact of Carmen La Rosa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmen La Rosa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmen La Rosa more than expected).

Fields of papers citing papers by Carmen La Rosa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmen La Rosa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmen La Rosa. The network helps show where Carmen La Rosa may publish in the future.

Co-authorship network of co-authors of Carmen La Rosa

This figure shows the co-authorship network connecting the top 25 collaborators of Carmen La Rosa. A scholar is included among the top collaborators of Carmen La Rosa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmen La Rosa. Carmen La Rosa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Personally-tailored opioid-overdose and medication for opioid use disorder (MOUD) education (TOME) significantly increases MOUD and overdose knowledge in peripartum individuals: Results from a randomized controlled pilot trial 2025 ·Drug and Alcohol Dependence ·Theresa Winhusen,Frankie Kropp,Marcela C. Smid,Jessica L Young,(unknown),Daniel Lewis,Carmen La Rosa,(unknown),Elizabeth E. Krans,Candace Hodgkins,Gerald Cochran,Michelle R. Lofwall	0
2	Long-term Safety of MK-5475 in Pulmonary Arterial Hypertension (PAH): Results from the Phase 2 INSIGNIA-PAH Extension Period 2025 ·American Journal of Respiratory and Critical Care Medicine ·Paul M. Hassoun,Marc Humbert,Kelly Chin,Guillermo Bortman,Humberto García‐Aguilar,Carmen La Rosa,Michael J. Ford,Wei Fu,Pei Niu,María José Loureiro,Marius M. Hoeper	0
3	MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study 2024 ·European Respiratory Journal ·Marc Humbert,Paul M. Hassoun,Kelly Chin,Guillermo Bortman,Mahesh J. Patel,Carmen La Rosa,(unknown),María José Loureiro,Marius M. Hoeper	3
4	Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial 2024 ·The Lancet Respiratory Medicine ·Surinder S. Birring,Linda Cardozo,Roger R. Dmochowski,Peter V. Dicpinigaitis,Amna Afzal,Carmen La Rosa,Susan Lu,Allison Martin Nguyen,Ruji Yao,Paul A. Reyfman	1
5	S1 A phase 3b trial of gefapixant, a P2X3-receptor antagonist, in women with chronic cough and stress urinary incontinence 2023 ·SS Birring,L. Cardozo,Peter V. Dicpinigaitis,Roger R. Dmochowski,(unknown),Carmen La Rosa,Susan Lu,Allison Martin Nguyen,(unknown),(unknown)	1
6	Prescription Opioid Dose Reductions and Potential Adverse Events: a Multi-site Observational Cohort Study in Diverse US Health Systems 2023 ·Journal of General Internal Medicine ·Verena E. Metz,G. Thomas Ray,Vanessa A. Palzes,Ingrid A. Binswanger,Andrea Altschuler,(unknown),Brian K. Ahmedani,Susan E. Andrade,Joseph A. Boscarino,Robin E. Clark,Irina V. Haller,Rulin C. Hechter,Douglas W. Roblin,Katherine Sanchez,Steffani R. Bailey,Dennis McCarty,Kari A. Stephens,Carmen La Rosa,(unknown),Cynthia I. Campbell	8
7	A Phase 3b Trial of Gefapixant, A P2X3-receptor Antagonist, in Women With Chronic Cough and Stress Urinary Incontinence 2023 ·Surinder S. Birring,L. Cardozo,(unknown),Roger R. Dmochowski,(unknown),Carmen La Rosa,Susan Lu,Allison Martin Nguyen,(unknown),(unknown)	1
8	Implementation of substance use screening in rural federally-qualified health center clinics identified high rates of unhealthy alcohol and cannabis use among adult primary care patients 2023 ·Addiction Science & Clinical Practice ·Jennifer McNeely,Bethany McLeman,(unknown),(unknown),(unknown),Sarah Farkas,Aimee Wahle,(unknown),Margaret C. Kline,(unknown),Carmen La Rosa,Lisa A. Marsch,John Rotrosen,Leah Hamilton	4
9	Validation and Meaningful Change Thresholds for an Objective Cough Frequency Measurement in Chronic Cough 2022 ·Lung ·Jonathan Schelfhout,Allison Martin Nguyen,Surinder S. Birring,Elizabeth D. Bacci,Margaret Vernon,David Muccino,Carmen La Rosa,John A. Smith	12
10	A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough 2022 ·Allergology International ·Akio Niimi,Hironori Sagara,Masashi Kikuchi,(unknown),Asako Sato,(unknown),Carmen La Rosa,David Muccino	10
11	Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough 2022 ·Annals of Allergy Asthma & Immunology ·Peter V. Dicpinigaitis,Surinder S. Birring,Michael S. Blaiss,Lorcan McGarvey,Alyn H. Morice,Ian Pavord,Imran Satia,John A. Smith,Carmen La Rosa,Qing Li,Allison Martin Nguyen,Jonathan Schelfhout,Anjela Tzontcheva,David Muccino	16
12	Applying interpretable deep learning models to identify chronic cough patients using EHR data 2021 ·Computer Methods and Programs in Biomedicine ·Xiao Luo,(unknown),(unknown),Wei Shao,Zhi Han,(unknown),Vladimir Turzhitsky,Vishal Bali,(unknown),Megan Metzger,(unknown),Carmen La Rosa,Jessica Weaver,Paul Dexter,Kun Huang	18
13	Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough 2020 ·ERJ Open Research ·David Muccino,Alyn H. Morice,Surinder S. Birring,Peter V. Dicpinigaitis,Ian Pavord,Christopher Assaid,Huub Jan Kleijn,Azher Hussain,Carmen La Rosa,Lorcan McGarvey,John A. Smith	42
14	A Phase 3b Trial Evaluating the Efficacy of Gefapixant in Reducing Stress Urinary Incontinence in Women with Chronic Cough 2020 ·SS Birring,L. Cardozo,Roger R. Dmochowski,Carmen La Rosa,(unknown),Allison Martin Nguyen,Jonathan Schelfhout,(unknown),Susan Lu	1
15	Using digital technologies in clinical trials: Current and future applications 2020 ·Contemporary Clinical Trials ·Carmen La Rosa,Lisa A. Marsch,Erin L. Winstanley,(unknown),Aimee Campbell	48
16	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies 2019 ·British Journal of Dermatology ·Alexa B. Kimball,Kim Papp,Kristian Reich,Melinda Gooderham,Q. Li,N. Cichanowitz,Carmen La Rosa,Andrew Blauvelt	23
17	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials 2018 ·British Journal of Dermatology ·Andrew Blauvelt,Kristian Reich,Kim Papp,Alexa B. Kimball,Melinda Gooderham,Stephen K. Tyring,Rodney Sinclair,Diamant Thaçi,Q. Li,N. Cichanowitz,(unknown),Carmen La Rosa	60
18	EFFECT OF TILDRAKIZUMAB ON PERSONAL RELATIONSHIPS IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS 2018 ·Kim Papp,Alexa B. Kimball,Andrew Blauvelt,Kristian Reich,Melinda Gooderham,Stephen K. Tyring,Rodney Sinclair,Diamant Thaçi,Yang Zhao,N. Cichanowitz,Qing Li,Carmen La Rosa	1
19	Using e-technologies in clinical trials 2015 ·Contemporary Clinical Trials ·Carmen La Rosa,Aimee Campbell,Gloria M. Miele,(unknown),Erin L. Winstanley	105
20	Issues in Designing and Implementing a Spanish‐Language Multi‐Site Clinical Trial 2007 ·American Journal on Addictions ·Lourdes Suarez‐Morales,(unknown),Steve Martino,Samuel A. Ball,Carmen La Rosa,(unknown),José Szapocznik,Kathleen M. Carroll	24

About Carmen La Rosa

Carmen La Rosa is a scholar working on Emergency Medical Services, Gastroenterology and Physiology, having authored 71 papers that have together received 1.8k indexed citations. Recurring topics across this work include Respiratory and Cough-Related Research (22 papers), Asthma and respiratory diseases (13 papers) and Voice and Speech Disorders (12 papers). The work is most often cited by research in Dermatology (343 citations), Immunology (496 citations) and Physiology (472 citations). Carmen La Rosa has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Qing Li, Kim Papp, Kristian Reich, Aimee Campbell, N. Cichanowitz, Andrew Blauvelt, Alexa B. Kimball, Diamant Thaçi, David Muccino and Rodney Sinclair. Their work appears in journals such as The Lancet, American Journal of Respiratory and Critical Care Medicine and Journal of Consulting and Clinical Psychology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact